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Abstract: Immune checkpoint inhibitors have revolutionized treatment and outcome of melanoma
and many other solid malignancies including non-small cell lung cancer (NSCLC) and renal cell
carcinoma (RCC). Unfortunately, only a minority of patients have a long-term benefit, while the
remaining demonstrate primary or acquired resistance. Recently, it has been demonstrated that the
prevalence of programmed death-ligand 1 (PD-L1) and tumor-infiltrating lymphocytes (TILs) varies
based on the anatomical site of metastases. In particular, liver seems to have more immunosuppressive
microenvironment while both the presence of lymph nodal disease and lung metastases seem to have
the highest prevalence of PD-L1 and TILs. The aim of the present study is to investigate the possible
role of site of metastases as a predictive factor for response or resistance to immunotherapy in several
types of cancer. In this multicenter retrospective study, we enrolled patients with metastatic NSCLC,
melanoma, RCC, urothelial, merkel carcinoma, and colon cancer who received immunotherapy from
April 2015 to August 2019. Major clinicopathological parameters were retrieved and correlated with
patients’ survival outcomes in order to assess their prognostic value and build a useful tool to assist
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in the decision-making process. A total of 291 patients were included in this study. One hundred
eighty-seven (64%) patients were male and 104 (36%) female. The tumor histology was squamous
NSCLC in 56 (19%) patients, non-squamous NSCLC in 99 (34%) patients, melanoma in 101 (35%)
patients, RCC in 28 (10%) patients, and other tumors in the remaining 7 (2%) patients. The number
of metastatic sites was 1 in 103 patients (35%), 2 in 104 patients (36%) and 3 in 84 patients (29%).
Out of 183 valuable patients, the entity of response was complete response (CR), partial response
(PR), stable disease (SD), and progression disease (PD) in 15, 53, 31, and 79 patients, respectively.
Using an univariate analysis (UVA), tumor burden (p = 0.0004), the presence of liver (p = 0.0009),
bone (p = 0.0016), brain metastases (p < 0.0001), the other metastatic sites (p = 0.0375), the number of
metastatic sites (p = 0.0039), the histology (p = 0.0034), the upfront use of immunotherapy (p = 0.0032),
and Eastern Cooperative Oncology Group (ECOG) Perfomance status (PS) ≥ 1 (p < 0.0001) were
significantly associated with poor overall survival (OS). Using a multivariate analysis (MVA) the
presence of liver (p = 0.0105) and brain (p = 0.0026) metastases, the NSCLC diagnosis (p < 0.0001)
and the ECOG PS (p < 0.0001) resulted as significant prognostic factors of survival. Regarding the
progression free survival (PFS), using a UVA of the tumor burden (p = 0.0004), bone (p = 0.0098)
and brain (p = 0.0038) metastases, the presence of other metastatic sites (p = 0.0063), the number
of metastatic sites (p = 0.0007), the histology (p = 0.0007), the use of immunotherapy as first line
(p = 0.0031), and the ECOG PS ≥ 1 (p ≤ 0.0001) were associated with a lower PFS rate. Using an
MVA, the presence of brain (p = 0.0088) and liver metastases (p = 0.024) and the ECOG PS (p < 0.0001)
resulted as predictors of poor PFS. Our study suggests that the site of metastases could have a role
as prognostic and predictive factor in patients treated with immunotherapy. Indeed, regardless of
the histology, the presence of liver and brain metastases was associated with a shorter PFS and OS,
but these results must be confirmed in further studies. In this context, a deep characterization of
microenvironment could be crucial to prepare patients through novel strategies with combination or
sequential immunotherapy in order to improve treatment response.
Keywords: immunotherapy; agnostic biomarkers; predictive factors; prognostic factors; metastatic
sites; melanoma; NSCLC; RCC
1. Introduction
The advent of immunotherapy represents a revolutionary event for the treatment of cancer
especially for melanoma, advanced non-small-cell lung cancer (NSCLC), renal cell carcinoma (RCC),
breast cancer, head and neck, and urothelial cancer both in metastatic and adjuvant settings.
The immune checkpoint inhibitors (ICIs) currently used in clinical practise include the antibody
anti-cytotoxic T lymphocyte antigen-4 (CTLA-4 inhibitor) ipilimumab, anti-programmed death 1
(anti PD-1) (nivolumab and pembrolizumab) and anti-programmed death-ligand 1 (anti PD-L1)
(atezolizumab, avelumab, and durvalumab) were used as monotherapies as well as in combination
with other anticancer drugs [1–5].
These agents have a favorable toxicity profile than chemotherapy or targeted therapies offering
the promise of durable clinical benefit, albeit only for a minority of patients [6–10].
Today, the real goal is the selection of the ideal patient who can receive immunotherapy through
the identification of specific biomarkers. In particular, programmed death-ligand 1 (PD-L1) expression
has been studied in lung cancer, bladder cancer, RCC and breast cancer in order to define its putative
prognostic and predictive value even though several limitations have been highlighted [11–14]. Indeed,
to date the PD-L1 expression is available in clinical practice only for the choice of treatment of
NSCLC [15–20] and breast cancer patients [21–24].
Furthermore, in lung cancer, tumor mutational burden, on tumor tissue and on circulating tumor
DNA (ctDNA), has been investigated [25,26], as a potential biomarker for responsiveness/resistance
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to immunotherapy. In breast cancer, the levels of tumor-infiltrating lymphocytes (TILs) may also be
considered as prognostic factors [27–31].
In the context of novel biomarkers, indoleamine 2,3-dioxygenase (IDO) [32,33], the enzymes
family involved in tryptophan catabolism, CD73, an immunosuppressive ecto-enzyme involved
in the production of adenosine [34–38], and microbiome [39–41] seem to have a promising role.
The complete and comprehensive immune profile requires simultaneous and dynamic evaluation of
many biomarkers that cooperate for the success or failure of the immune response, rather than research
on a single biomarker.
Some clinical features are under evaluation to predict the response to immunotherapy [42].
In particular, liver metastases are considered a predictor of worse prognosis in lung cancer, melanoma,
and gastrointestinal cancer patients [43] such as the pleuric effusion and brain metastases.
In this scenario, we have already performed a nomogram to predict response to nivolumab in a
lung cancer cohort of patients [44].
The aim of the present study is to investigate the agnostic role of the metastasis site as a predictive
response or resistance factor to immunotherapy in several types of cancer.
2. Materials and Methods
2.1. Patients, Treatment, and Outcomes
From April 2015 to August 2019, patients with metastatic NSCLC, melanoma, RCC, urothelial,
Merkel carcinoma, and colon-cancer receiving immunotherapy from five different hospitals were
enrolled into this retrospective study. Patients were clinically staged with contrast enhanced computed
tomography (CT) scan and, if clinically indicated, magnetic resonance imaging (MRI).
The final version of the protocol was approved by the Institutional Ethics Committee (Ethical
Committee no. 4421, “Sapienza University”).
Nivolumab, pembrolizumab, atezolizumab, and avelumab were administered intravenously
according to approved schedule until disease progression or development of unacceptable toxicity.
Tumor response was assessed every 8–12 weeks using immune-related Response Evaluation Criteria
in Solid Tumors (i-RECIST) and classified as complete response (RC), partial response (RP), stable
disease (SD), and progressive disease (PD). Toxicities were recorded at day 1 of every cycle and
classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events
(version 4.0). Baseline patients’ clinical condition has been defined with Eastern Cooperative Oncology
Group (ECOG) Performance Status (PS).
Progression-free survival (PFS) was defined as the time from patient’s first administration of
ICIs until the first progression or in-treatment death. The OS was defined as the time from patient
registration to death from any cause. Tumor burden was defined as ‘low’ (≤2 metastatic sites) or ‘high’
(>2 metastatic sites). Patients who did not have an event during the observation time (PD or death) are
described as censored.
2.2. Statistical Analysis
In the descriptive analysis, quantitative variables were described as mean and range, while
qualitative variables as number and percentage and they were analyzed with Fisher’s exact test or
Pearson’s Chi-square test. The association of clinic-pathological characteristics and OS and PFS was
analyzed by both the univariate and multivariate analyses (UVA and MVA, respectively). PFS and OS
were estimated using the Kaplan–Meier method, prognostic clinic-pathological variables deemed of
potential relevance with the UVA (assuming a cutoff of p < 0.10) were included in the MVA analysis.
Discrimination of nomogram was tested by Kaplan–Meier curves and boxplots. A p < 0.05 was
considered statistically significant. Statistical analyses were performed using R-package software.
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3. Results
Two hundred ninety-one metastatic patients treated with ICIs were enrolled in this study.
The baseline clinical and pathological characteristics, including gender, ECOG PS, histology, primary
sites, previous treatment, number, and sites of metastases are reported in Table 1.
Table 1. Baseline characteristics and demographics.
Characteristics Patients N (%)
Gender
Male 187 64%
Female 104 36%
Histology
NSCLC 1 squamous 56 19%
NSCLC 1 non
squamous
99 34%
Melanoma 101 35%
RCC 2 28 10%
Other 7 2%
Metastatic Sites
1 103 35%
2 104 36%
3 84 29%
Sites of Metastases
Lymph node 140 48%
Liver 59 20%
Lung 185 64%
Bone 75 26%
Brain 42 14%
ECOG PS 3
0 146 50%
1 102 35%
2 42 15%
1 NSCLC: non-small cell lung cancer; 2 RCC: renal cell carcinoma; 3 ECOG PS Eastern Cooperative Oncology Group
Performance Status.
One hundred eighty-seven (64%) patients were male and 104 (36%) female. The tumor histology
was squamous NSCLC in 56 (19%), non-squamous NSCLC in 99 (34%), melanoma in 101 (35%), clear
cell RCC in 28 (10%) and other tumors in the remaining 7 (2%) patients. Baseline ECOG PS, evaluated
at the beginning of immunotherapy, was 0, 1, and 2 in 146 (50%), 102 (35%%), 42 (15%) patients,
respectively at the baseline imaging evaluation with CT scan, the number of metastatic sites was 1 in
103 patients (35%), 2 in 104 patients (36%), and 3 in 84 patients (29%) as expected based on the natural
history of each tumor type. The most frequent metastatic site was lung, detected in 185 patients (64%),
and followed by lymph nodes (48%). Bone, liver and brain metastases were detected in 75 (26%), 59
(20%), and 42 (14%) of patients respectively. Data related to immunotherapy are shown in Table 2.
In most cases the immunotherapy was planned as a first line treatment (51%). Overall, 94% of patients
received immunotherapy as first, second, or third line and the remaining 6% received immunotherapy
beyond the fourth line. The most frequently used ICIs were nivolumab (75%) and pembrolizumab
(21%), while the anti PD-L1 atezolizumab and avelumab were used in 11 and 1 patients respectively.
One hundred and eighty-three out of 291 patients were evaluable for best response to ICIs. Fifteen CR
(8%), 53 PR (29%), and 31 SD (17%) were achieved. Overall, disease progression occurred in 79 patients
(43%) (Table 2). No high-grade toxicities were reported.
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Table 2. Immunotherapy treatments and best response.
Characteristics Patients N (%)
Immunotherapy Regimen
Nivolumab 219 75%
Pembrolizumab 60 21%
Atezolizumab 11 4%
Avelumab 1 0%
Durvalumab 0 0%
Line of Treatment with Immunotherapy
1st 94 32%
2nd 147 51%
3rd 33 11%
4th 11 4%
5th or more 4 2%
Best Response to Immunotherapy
PD 79 43%
CR 15 8%
PR 53 29%
NV 5 3%
SD 31 17%
ALL 183 100%
Response Evaluation Criteria in Solid Tumors Criteria (i-RECIST): complete response (RC); partial response (RP);
stable disease (SD); progressive disease (PD).
A possible association between disease progression, clinical and pathological characteristics and
previous treatment is shown in the Table 3.
Performing a univariate analysis, tumor burden (p = 0.0004), the presence of liver (Figure 1a,
p = 0.0009), bone (Figure 1b, p = 0.0016), brain metastases (Figure 1c, p < 0.0001), the other metastatic
sites (p = 0.0375), the number of metastatic sites (Figure S1, p = 0.0039) and ECOG PS ≥ 1 (Figures S2
and S3, p < 0.0001) were significantly associated with lower OS (Table 3). Moreover, we evaluated the
impact of immunotherapy in first line versus second or subsequent lines. Patients treated upfront with
immunotherapy had a better OS compared to a later administration (Figure 1d, p = 0.0022). Furthermore,
we evaluated OS between different cancer histologies, highlighting a worse prognosis in patients
affected by both squamous and non-squamous NSCLC compared to other cancers (Figure 1e,f, p < 0.001
and p = 0.0044 respectively). The 24-month OS fraction evaluated for several patients’ characteristics is
reported in Table 4. Using a MVA of the use of upfront ICIs did not result as independent predictor.
The metastatic site of liver (p = 0.0051) and brain (p = 0.0021), the NSCLC histology (both squamous
and non-squamous, p < 0.0001) and the ECOG PS (p < 0.0001) were confirmed as prognostic factors at
the multivariate analysis (Table 5).
Table 3. Univariate analysis for overall survival and progression free survival.
Characteristics OS PFS
Hazard Ratio (95% CI) p-Value Hazard Ratio (95% CI) p-Value
Age ≥ 70 0.833 (0.568 to 1.191) 0.302 1.044 (0.759 to 1.449) 0.7716
Gender 1.140 (0.797 to 1.653) 0.4571 1.174 (0.874 to 1.618) 0.2705
Tumor burden 0.545 (0.369 to 0.749) 0.0004 0.635 (0.448 to 0.817) 0.0011
Lymphnodes 1.173 (0.833 to 1.691) 0.3413 1.215 (0.919 to 1.673) 0.1585
Liver 0.546 (0.293 to 0.727) 0.0009 0.728 (0.458 to 1.005) 0.0535
Bone 0.575 (0.334 to 0.774) 0.0016 0.679 (0.436 to 0.892) 0.0098
Brain 0.431 (0.168 to 0.507) <0.0001 0.593 (0.307 to 0.796) 0.0038
Other met sites 1.476 (1.022 to 2.140) 0.0375 1.518 (1.131 to 2.113) 0.0063
N of metastatic sites > 2 0.818 (0.312 to 1.999) 0.6198 1.303 (0.609 to 2.746) 0.5025
Diagnosis(NSCLC vs. other) 2.277 (1.254 to 3.143) 0.0034 2.093 (1.320 to 2.822) 0.0007
ECOG PS ≥ 1 0.281 (0.170 to 0.356) <0.0001 0.446 (0.275 to 0.518) <0.0001
Line (I vs. II or more) 0.566 (0.398 to 0.831) 0.0032 0.632 (0.459 to 0.854) 0.0031
Eastern Cooperative Oncology Group (ECOG) performance status (PS); OS: overall survival; PFS: progression
free survival.
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Table 4. 24-month overall survival (%).
Characteristics 24-M OS Group 1 (%) 24-M OS Group 2 (%)
Tumor burden (low vs. high) 49.7 31.5
Liver met. (no vs. yes) 42.6 30.5
Bone met. (no vs. yes) 43.5 31
Brain met. (no vs. yes) 44.5 17
ECOG PS (0 vs. ≥1) 60 20.4
Diagnosis (other vs. NSCLC) 58.6 17.1
Line (1st vs. 2nd or more) 51.4 34.3
Table 4 shows patients 24 months overall survival for different characteristic. Each characteristic is declined as
dichotomous variable. Group 1 column indicates 24 months OS for the first modality and Group 2 column for the
second modality of each variable (characteristic). 24-month OS is expressed as % of patients alive at 24 months.
Table 4 footnotes: Eastern Cooperative Oncology Group (ECOG) performance status (PS); OS: overall survival; PFS:
progression free survival; Met.: metastases; NSCLC: non-small cell lung cancer.
Table 5. Multivariate analysis for OS
MVA for Overall Survival (p < 0.0001)
Covariate b Exp (b) 95% CI of Exp (b) p
Liver 0.5512 1.7353 1.1824 to 2.5467 0.0051
Brain 0.4889 1.6306 1.0786 to 2.4650 0.0211
NSCLC vs. others −1.3823 0.251 0.1707 to 0.3691 <0.0001
ECOG PS 0.8449 2.3278 1.8642 to 2.9067 <0.0001
Table 5 shows that liver and brain metastases are independent predictors of poor OS regardless of histology
(p = 0.0051 and p = 0.0211 respectively). Table 5 footnotes: MVA: multivariate analysis; OS: overall survival: NSCLC:
non-small cell lung cancer; Eastern Cooperative Oncology Group (ECOG) performance status (PS). Significant
p-value in bold.
Figure 1a shows the OS difference in patients with and without liver metastases pink line: patients
with liver metastases; blue line: patients without liver metastases; OS: overall survival; Tick marks
indicate censored data.
Figure 1b shows OS difference in patients with and without brain metastases (p < 0.0001) pink
line: patients with brain metastases; blue line: patients without brain metastases; OS: overall survival.
Tick marks indicate censored data.
Figure 1c shows the OS difference in patients with and without bone metastases (p < 0.0016) pink
line: patients with bone metastases; blue line: patients without bone metastases; OS: overall survival.
Tick marks indicate censored data.
Figure 1d shows the OS difference in patients treated with immunotherapy in fist line vs. second
or subsequent lines (p < 0.0022) pink line: first line; blue line: subsequent lines; OS: overall survival.
Tick marks indicate censored data.
Figure 1e shows the OS in patients affected by different cancers (p < 0.0001) red line (1): NSCLC
squamous; yellow line (2): NSCLC non squamous; light green line (3): melanoma; dark green line
(4): RCC; light blue line (5): Urothelial cancer; violet line (6): merkel cell; pink line (7): colon; OS:
overall survival; NSCLC: non-small cell lung cancer; RCC: renal cell carcinoma Tick marks indicate
censored data.
Figure 1f shows the OS in patients affected by both squamous and non-squamous NSCLC versus
patients affected by other cancer histologies. blue line: NSCLC squamous and non-squamous; pink
line: other histologies; OS: overall survival; NSCLC: non-small cell lung cancer; Tick marks indicate
censored data.
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Figure 1. (a) OS in patients with and without liver metastases; (b) OS in patients with and without
brain metastases; (c) OS in patients with and without bone metastases; (d) OS in patients treated with
immunotherapy upfront or in subsequent lines; (e) OS in different histologies; (f) OS in patients affected
by squamous and non-squamous NSCLC or other cancers.
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Based on the estimated regression coefficients in the Cox analysis, a prognostic nomogram
including the presence of liver and brain metastases, ECOG PS, and histology was developed
to assign survival probability at 12 and 24 months (Figure 2a,b, respectively) in patients treated
with immunotherapy. The prognostic nomogram was developed including parameters which
were significant to multivariate analysis to assign survival probability at 12 and 24 months after
immunotherapy treatment commencement. Kaplan-Meier curves, according to the range of total
points, highlighted the appropriateness of distinguish the patients’ survival in all the subgroups. Based
on the result obtained with the nomogram on the studied population, we divided the patients into
quartiles (group from 0 to 3). We highlighted a significant difference in OS between groups, confirming
the predictive efficacy of the nomogram (Figure 3, p < 0.001).
Figure 2a,b: To use the nomogram, a vertical line needs to be delineated to the point raw to
assign point values for each variable. Thereafter, the corresponding points are to be summed to
obtain the total points. Finally, from the total points a vertical line needs to be drawn to get the
value of 24-month OS probability. The presence of liver and brain metastases corresponds to 21 and
20 points, respectively, while the ECOG PS of 0 corresponds to 0 points. A diagnosis of cancer different
from NSCLC correspond to 0 points. The C-indexes for OS models was 0.797 and calibration of
the nomogram for OS was considered adequate (Figures S3 and S4). Figure 2a,b footnotes: Eastern
Cooperative Oncology
To use the nomogram, a vertical line needs to be delineated to the point raw to assign point
values for each variable. Thereafter, the corresponding points are to be summed to obtain the total
points. Finally, from the total points, a vertical line needs to be drawn to get the value of 12-month PFS
probability. Histologies have a larger impact on PFS, taking into account the different natural history
and timing of immunotherapy treatment in different cancers. For this reason, cancer histology has
been specified in this PFS nomogram. The C-indices for PFS models were 0.665 and the calibration of
the nomogram for PFS was considered adequate.
Diagnosis: 0—squamous NSCLC; 1—non-squamous NSCLC; 2—melanoma; 3—RCC; 4—urothelial
cancer; 6—Merkel; 7—other histologies. Figure 2b footnotes: NSCLC: non-small cell lung cancer; RCC:
renal cell carcinoma; Eastern Cooperative Oncology Group (ECOG) performance status (PS); PFS:
progression free survival.
Figure 3 shows the OS difference in patients divived in quartile using the OS nomogram result
(p < 0.0001). Red line: patients in the fourth quartile (75 to 100); green line: patients in the third
quartile; blue line: patients in the second quartile; purple line: patients in the first quartile using the
OS nomogram; OS: overall survival. Tick marks indicate censored data.
Using a UVA of the tumor load (p = 0.0011), the presence of bone (Figure 4c, p = 0.0098), brain
(Figure 4b, p = 0.0038) metastases, the presence of other metastatic sites (p = 0.0063), the number of
metastatic sites (Figure S5, p = 0.0007) and the ECOG PS ≥ 1 (Figure S6; p = <0.0001) were associated to
a poor PFS (Table 2). The presence of liver metastases showed a tendency to be statistically significant
and was included in the subsequent MVA (Figure 4a, p = 0.0535). Moreover, as previously done for the
OS analysis, we performed a UVA to evaluate the impact of upfront or subsequent treatment with
immunotherapy. First line treatment resulted in an improved PFS (Figure 4d, p < 0.003), but this trend
was not confirmed at MVA. Finally, NSCLC patients’ subgroup had a worse PFS compared to the others
(Figure 4e,f, p < 0.0001 and p = 0.0068 respectively). A significant association between an impaired
PFS and the presence of brain metastases (p = 0.0088), liver metastases (p = 0.024) was confirmed with
the MVA. Brain and liver metastases were confirmed as independent predictors of poor response to
immunotherapy. Moreover, NSCLC diagnosis (p = 0.0001) and ECOG PS (p < 0.0001) were also strong
predictors of poor clinical outcomes (Table 6).
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Figure 4. (a) PFS in patients with and without liver metastases; (b) PFS in patients with and without
brain metastases; (c) PFS in patients with and without bone metastases; (d) PFS in patients treated
with immunotherapy upfront or in subsequent lines; (e) PFS in different histologies; (f) PFS in patients
affected by squamous and non-squamous NSCLC or other cancers.
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Table 6. Multivariate analysis for PFS.
MVA for PFS (p < 0.0001)
Covariate b Exp (b) 95% CI of Exp (b) p
Liver 0.4003 1.4923 1.0563 to 2.1082 0.0239
Brain 0.4151 1.5145 1.0359 to 2.2142 0.0088
NSCLC vs. others −0.6067 0.5451 0.4642 to 0.6402 <0.0001
ECOG PS 0.8243 2.2802 1.6958 to 3.0660 <0.0001
Table 6 shows that liver and brain metastases are independent predictors of poor PFS regardless of histology
(p = 0.0243 and p = 0.0088 respectively). Table 6 footnotes: MVA: multivariate analysis; PFS: progression free
survival; NSCLC: non-small cell lung cancer; Eastern Cooperative Oncology Group (ECOG) performance status
(PS). Significant p-value in bold.
Figure 4a shows the PFS difference in patients with and without liver metastases (p = 0.054) pink
line: patients with liver metastases; blue line: patients without liver metastases; PFS: Progression Free
Survival. Tick marks indicate censored data.
Figure 4b shows the PFS difference in patients with and without brain metastases (p = 0.0038) pink
line: patients with brain metastases; blue line: patients without brain metastases; PFS: Progression
Free Survival. Tick marks indicate censored data.
Figure 4c shows the PFS difference in patients with and without bone metastases (p = 0.0098) pink
line: patients with bone metastases; blue line: patients without bone metastases; PFS: Progression Free
Survival. Tick marks indicate censored data.
Figure 4d shows the PFS in patients treated with immunotherapy upfront or later (p = 0.0031) pink
line: patients treated with immunotherapy as first line; blue line: patients treated with immunotherapy
as second or later lines; PFS: progression free survival. Tick marks indicate censored data.
Figure 4e shows the PFS in patients affected by different cancers (p < 0.0001) red line (1): NSCLC
squamous; yellow line (2): NSCLC non squamous; light green line (3): melanoma; dark green line
(4): RCC; light blue line (5): Urothelial cancer; violet line (6): Merkel cell; pink line (7): colon; PFS:
progression free survival; NSCLC: non-small cell lung cancer; RCC: renal cell carcinoma. Tick marks
indicate censored data.
Figure 4f shows the PFS in patients affected by both squamous and non-squamous NSCLC
versus patients affected by other cancer hystologies (p = 0.00068). blue line: NSCLC squamous and
non-squamous; pink line: other histologies; PFS: progression free survival; NSCLC: non-small cell
lung cancer. Tick marks indicate censored data.
Based on the estimated regression coefficients in the Cox analysis, a prognostic nomogram that
included liver and brain metastases, diagnosis, and ECOG PS was developed to assign the PFS
probability at 12 months (Figure 2b) after immunotherapy treatment commencement.
4. Discussion
Immunotherapy has radically changed the approach to the cancer patient in hard to treat
malignancies. Nevertheless, the large phase III studies showed that only a subset of patient’s benefits
from immunotherapy, with lasting responses and very limited side effects. Patient’s selection of
treatment is becoming a dominant issue to avoid unnecessary progressions of disease and improving
the overall outcome. Moreover, the data available to date do not allow us to identify predictive
biomarkers of response to the treatment with anti PD-1, anti PD-L1 and anti CTLA 4. Aware of
the difficulty of finding a reliable biomarker in the complex and dynamic immune system, research
is focusing on what would appear to be a surrogate such as tumor mutational burden or other
molecular signatures.
In this regard, some clinical features (ECOG PS, lactate dehydrogenase, etc.) would seem to be
able to drive the choice of treatment even if the immunological rationale is not always clear.
In this context, it is also known how the immunological microenvironment of metastatic disease can
be different considering the specific organ, with a possible impact on the response to immunotherapy.
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The site of the metastases, regardless of the primitive cancer, impacts in our study on the response
to immunotherapy as well as on the prognosis, suggesting that the site of metastasis could have an
agnostic predictive and prognostic role in predicting response to immunotherapy. Our data point
as disease progression is related to the specific site of metastases, which influences the site-specific
progression. Furthermore, the few responses to treatment in liver and brain metastatic sites have been
limited and transient.
Indeed, regardless of the histology, in patients treated with immunotherapy the presence of liver
or brain metastases seems to be associated with a shorter PFS and OS, as previously demonstrated in
NSCLC [44] and melanoma [45]. The biological rationale has not yet been fully explained but some
preliminary data in the literature support the idea of considering the immune system as a specific organ.
To date, the role of metastatic disease in the liver is considered as a negative predictive and
prognostic factor related to patients receiving chemotherapy-based treatment, including multimodal
and aggressive strategy.
However, in the novel context of immunotherapy and immune biomarkers, the liver site of
metastasis appears to play a relevant negative predictive role in tumor response. In particular, it
was demonstrated that the poor response to immunotherapy is associated with liver metastasis in
melanoma patients treated with ipilimumab and nivolumab [45] and in NSCLC patients treated with
nivolumab [43,44]. The peculiar immunological behavior of patients with liver metastases could be
related to the immunological context of liver microenvironment that seems to be ‘colder’ than the
primary tumor or than another metastatic site such as lung or lymph node. Several mechanisms of
immune-escape have been postulated, such as the incomplete activation of CD8+ lymphocytes T
(T cells), the trapping and the deletion of activated CD8+ cells, the inefficient activity of CD4+ T cells,
and the activation of regulatory T cells by Kupffer cells [45].
Brain metastases occur in 20% of cancer patients, especially in those with lung, breast, melanoma,
or renal cell carcinoma, determining a poor prognosis. The role of ICIs in these patients is an open issue
due to the poor results. Indeed, the use of ipilimumab as a single agent for melanoma brain metastases
resulted in disease control rates for only 10% and 25% of patients treated with or without steroids,
respectively. Single agent pembrolizumab was associated with an intracranial response rate in 33%
of patients in NSCLC and 22% in melanoma patients [46]. However, the role of brain metastases in
patients treated with ICIs can be explained through several mechanisms such as activation of regulatory
lymphocytes T (Treg), lymphopenia, reduction of T-cell responses, and deficiency of interleukin 2 (IL-2)
signaling that result in an immunosuppressive microenvironment [47].
Despite ICIs having shown significant activity on visceral disease, the efficacy in patients with
bone metastases is not well explored. Indeed, the predictive and prognostic role of bone metastases is
still controversial and unclear and it could be explained by the role of niches and pathologic bone loss
that could hinder immune activation, compromising long-lived memory T and B lymphocytes and the
production of cytotoxic T cell [48]. Interestingly, T-regs could be crucial in determining equilibrium
between osteoclastic and osteoblastic activity. Indeed, in rheumatic arthritis, it was demonstrated
that T-regs are characterized by bone protective effect by direct inhibition of osteoclastogenesis as a
negative feedback [49]. The unfavorable outcome in patients with bone metastases could be related to
a T-reg-enriched immunosuppressive microenvironment. Our study suggests that bone metastases
could be considered both predictive and prognostic factors, but further studies on a larger population
are needed.
Of note, applying a UVA to liver, bone, and brain metastases resulted in a significant association
with worse PFS and OS compared to other sites, while when using a MVA, only brain and liver
metastatic sites were confirmed as independent predictive and prognostic factors.
Indeed, these sites present several peculiar immunological behaviors representing a “bumper site
for immunotherapy” characterized by immune suppressive or immune cold microenvironment and
suggesting that we need to consider both circulating and organ-specific immunity.
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In order to translate these data into clinical practice, we have developed two nomograms for
OS and PFS, that are based on easily available and inexpensive clinical factors that have showed a
good performance in predicting individual PFS and OS probability among cancer patients treated with
immunotherapy. Building a predictive model of response to immunotherapy treatment is currently of
primary importance for clinicians and cancer patients. In our study, the site of metastatic spread was
able to condition the response to ICIs, PFS, and OS of patients regardless of the primary tumor and its
histology. Metastatic cell recognition and killing by lymphocytes seems to be dependent upon the
organ specific microenvironment that, if oriented to immune suppression, could result as a specific
immune sanctuary. The present study has some limitations to be acknowledged. This is a retrospective
cohort study thereby with potential for inherent biases. Still, external prospective validation is required
to assess reproducibility and generalizability of our results.
5. Conclusions
Specific sites of metastases could have an agnostic role in identifying patients resistant to upfront
mono-immunotherapy with anti-PD1/PD-L1 or anti-CTLA-4. In this context, a nomogram to predict
outcomes and a deep characterization of the site-specific microenvironment could be crucial to select
these patients with poor prognosis through novel strategies with combination or sequential drugs, to
overcome resistances and improve immunotherapy results.
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